Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to further improve their efficacy.
All Keywords
【저자키워드】 coronavirus, Vaccines, Therapeutics, MERS-CoV, Spike protein, Receptor-binding domain, 【초록키워드】 antibodies, Efficacy, Vaccine, Pathogenesis, Infection, MERS, Protein, RBD, therapeutic, structural proteins, Neutralizing, Critical, S-protein, Infectious virus, Middle East, domain, syndrome, ENCODE, feature, IMPROVE, reported, in viral, the S protein, MERS-CoV genome, 【제목키워드】 advance,
【저자키워드】 coronavirus, Vaccines, Therapeutics, MERS-CoV, Spike protein, Receptor-binding domain, 【초록키워드】 antibodies, Efficacy, Vaccine, Pathogenesis, Infection, MERS, Protein, RBD, therapeutic, structural proteins, Neutralizing, Critical, S-protein, Infectious virus, Middle East, domain, syndrome, ENCODE, feature, IMPROVE, reported, in viral, the S protein, MERS-CoV genome, 【제목키워드】 advance,